FI3793992T3 - Matriksin metalloproteinaasin (mmp) estäjiä ja niiden käyttömenetelmiä - Google Patents
Matriksin metalloproteinaasin (mmp) estäjiä ja niiden käyttömenetelmiä Download PDFInfo
- Publication number
- FI3793992T3 FI3793992T3 FIEP19731374.5T FI19731374T FI3793992T3 FI 3793992 T3 FI3793992 T3 FI 3793992T3 FI 19731374 T FI19731374 T FI 19731374T FI 3793992 T3 FI3793992 T3 FI 3793992T3
- Authority
- FI
- Finland
- Prior art keywords
- mmp
- sen
- patenttivaatimuksen
- tarpeessa
- olevassa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671753P | 2018-05-15 | 2018-05-15 | |
| PCT/US2019/032127 WO2019222154A1 (en) | 2018-05-15 | 2019-05-14 | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3793992T3 true FI3793992T3 (fi) | 2024-04-17 |
Family
ID=66690981
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19731374.5T FI3793992T3 (fi) | 2018-05-15 | 2019-05-14 | Matriksin metalloproteinaasin (mmp) estäjiä ja niiden käyttömenetelmiä |
| FIEP19728197.5T FI3793995T3 (fi) | 2018-05-15 | 2019-05-14 | Matriksin metalloproteinaasin (mmp) estäjiä ja niiden käyttömenetelmiä |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19728197.5T FI3793995T3 (fi) | 2018-05-15 | 2019-05-14 | Matriksin metalloproteinaasin (mmp) estäjiä ja niiden käyttömenetelmiä |
Country Status (20)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10532102B2 (en) * | 2016-08-19 | 2020-01-14 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition and methods of uses |
| SG11202011318QA (en) * | 2018-05-15 | 2020-12-30 | Foresee Pharmaceuticals Usa Inc | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
| DK4058437T3 (da) | 2019-11-14 | 2025-01-20 | Foresee Pharmaceuticals Usa Inc | Matrix-metalloproteinase-(MMP)-inhibitorer og fremgangsmåder til anvendelse heraf |
| JP2024520818A (ja) * | 2021-06-08 | 2024-05-24 | フォアシー ファーマシューティカルズ カンパニー リミテッド | 急性呼吸促迫症候群を処置するためのmmp阻害薬の使用 |
| KR20240019265A (ko) * | 2021-06-08 | 2024-02-14 | 포시 파마슈티컬스 컴퍼니 리미티드 | Mmp-12 억제제의 안전한 투여 |
| EP4198033A1 (en) | 2021-12-14 | 2023-06-21 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
| WO2023110473A1 (en) | 2021-12-14 | 2023-06-22 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2482618A1 (fr) | 1980-05-16 | 1981-11-20 | Inst Corps Gras Iterg | Procede de conjugaison catalytique de corps gras polyinsatures, produits obtenus et application |
| AU1817700A (en) | 1998-12-31 | 2000-07-24 | Aventis Pharmaceuticals Inc. | 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12 |
| US6352976B1 (en) | 1998-12-31 | 2002-03-05 | Aventis Pharmaceuticals Inc. | Selective inhibitors of MMP-12 |
| AU4882101A (en) | 2000-04-28 | 2001-11-12 | Shionogi & Co., Ltd. | Mmp-12 inhibitors |
| SE0100903D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| MXPA03008180A (es) * | 2001-03-15 | 2003-12-12 | Astrazeneca Ab | Inhibidores de metaloproteinasa. |
| ATE445400T1 (de) | 2001-05-25 | 2009-10-15 | Bristol Myers Squibb Co | Hydantion-derivate als hemmer von matrix- metalloproteinasen |
| EP1394159A1 (fr) | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| WO2004033632A2 (en) * | 2002-10-04 | 2004-04-22 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
| US7132432B2 (en) * | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
| ES2364068T3 (es) * | 2004-08-19 | 2011-08-24 | Quest Pharmaceutical Services | 5-[3-(4-benciloxifeniltio)-fur-2-il]-imidazolin-2,4-diona y sus análogos como inhibidores de macrófago elastasa. |
| JP5357365B1 (ja) | 2011-12-21 | 2013-12-04 | パナソニック株式会社 | データ処理装置、データ送信装置、データ処理システム、データ処理方法、及び、データ送信方法 |
| SG11202011318QA (en) * | 2018-05-15 | 2020-12-30 | Foresee Pharmaceuticals Usa Inc | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
-
2019
- 2019-05-14 SG SG11202011318QA patent/SG11202011318QA/en unknown
- 2019-05-14 KR KR1020207035504A patent/KR102861502B1/ko active Active
- 2019-05-14 FI FIEP19731374.5T patent/FI3793992T3/fi active
- 2019-05-14 PL PL19728197.5T patent/PL3793995T3/pl unknown
- 2019-05-14 ES ES19731374T patent/ES2984594T3/es active Active
- 2019-05-14 US US17/055,459 patent/US11739080B2/en active Active
- 2019-05-14 TW TW108116631A patent/TWI827601B/zh active
- 2019-05-14 DK DK19728197.5T patent/DK3793995T3/da active
- 2019-05-14 CN CN202411619226.XA patent/CN119462623A/zh active Pending
- 2019-05-14 FI FIEP19728197.5T patent/FI3793995T3/fi active
- 2019-05-14 EP EP19731374.5A patent/EP3793992B1/en active Active
- 2019-05-14 CN CN201980047375.4A patent/CN112424192B/zh active Active
- 2019-05-14 EP EP19728197.5A patent/EP3793995B1/en active Active
- 2019-05-14 US US17/055,483 patent/US12258335B1/en active Active
- 2019-05-14 HU HUE19731374A patent/HUE066627T2/hu unknown
- 2019-05-14 PT PT197281975T patent/PT3793995T/pt unknown
- 2019-05-14 TW TW108116632A patent/TWI798435B/zh active
- 2019-05-14 CA CA3100319A patent/CA3100319A1/en active Pending
- 2019-05-14 ES ES19728197T patent/ES2978192T3/es active Active
- 2019-05-14 AU AU2019270975A patent/AU2019270975B2/en active Active
- 2019-05-14 TW TW112115526A patent/TWI895726B/zh active
- 2019-05-14 CN CN201980047333.0A patent/CN112424186A/zh active Pending
- 2019-05-14 WO PCT/US2019/032127 patent/WO2019222154A1/en not_active Ceased
- 2019-05-14 AU AU2019269409A patent/AU2019269409B2/en active Active
- 2019-05-14 KR KR1020257002624A patent/KR20250021604A/ko active Pending
- 2019-05-14 US US16/411,336 patent/US20190352288A1/en not_active Abandoned
- 2019-05-14 LT LTEPPCT/US2019/032131T patent/LT3793995T/lt unknown
- 2019-05-14 SI SI201930733T patent/SI3793995T1/sl unknown
- 2019-05-14 SG SG11202011316RA patent/SG11202011316RA/en unknown
- 2019-05-14 EP EP24150920.7A patent/EP4349332B1/en active Active
- 2019-05-14 BR BR112020023269-6A patent/BR112020023269A2/pt unknown
- 2019-05-14 US US16/411,402 patent/US10851089B2/en active Active
- 2019-05-14 JP JP2021514292A patent/JP7343571B2/ja active Active
- 2019-05-14 HU HUE19728197A patent/HUE066619T2/hu unknown
- 2019-05-14 DK DK19731374.5T patent/DK3793992T3/da active
- 2019-05-14 CA CA3100320A patent/CA3100320A1/en active Pending
- 2019-05-14 EP EP24150915.7A patent/EP4335499A3/en active Pending
- 2019-05-14 MY MYPI2020005983A patent/MY199200A/en unknown
- 2019-05-14 JP JP2021514291A patent/JP7344959B2/ja active Active
- 2019-05-14 KR KR1020207035503A patent/KR102761591B1/ko active Active
- 2019-05-14 WO PCT/US2019/032131 patent/WO2019222157A1/en not_active Ceased
- 2019-05-14 PT PT197313745T patent/PT3793992T/pt unknown
-
2023
- 2023-07-06 US US18/347,674 patent/US12215096B2/en active Active
- 2023-08-31 JP JP2023140718A patent/JP2023164905A/ja active Pending
- 2023-09-04 JP JP2023142664A patent/JP7656669B2/ja active Active
-
2024
- 2024-01-18 AU AU2024200323A patent/AU2024200323B2/en active Active
- 2024-12-17 US US18/983,692 patent/US20250115590A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Casey et al. | Bank lending constraints, trade credit and alternative financing during the financial crisis: Evidence from European SMEs | |
| Zhou et al. | DEA frontier improvement and portfolio rebalancing: An application of China mutual funds on considering sustainability information disclosure | |
| Elshandidy et al. | Aggregated, voluntary, and mandatory risk disclosure incentives: Evidence from UK FTSE all-share companies | |
| GB201801679D0 (en) | Database transaction log writing and integrity checking | |
| Qiu et al. | Do target CEOs trade premiums for personal benefits? | |
| EP3776438A4 (en) | BLOCK CHAIN LOAN TRANSACTION SYSTEMS AND PROCEDURES | |
| Bernard et al. | Mean–variance optimal portfolios in the presence of a benchmark with applications to fraud detection | |
| Liu et al. | Robust multi-period portfolio model based on prospect theory and ALMV-PSO algorithm | |
| ATE519158T1 (de) | Wiederherstellung einer fehlgeschlagenen datenübertragung zwischen einem host und einer datenspeichervorrichtung | |
| Hsu et al. | Asset allocation strategies, data snooping, and the 1/N rule | |
| Moscone et al. | Real estate market and financial stability in US metropolitan areas: A dynamic model with spatial effects | |
| Dufrénot et al. | Spillover effects of the 2008 global financial crisis on the volatility of the Indian equity markets: Coupling or uncoupling? A study on sector-based data | |
| Bales et al. | Does the source of uncertainty matter? The impact of financial, newspaper and Twitter-based measures on US banks | |
| Jeon et al. | Valuing American floating strike lookback option and Neumann problem for inhomogeneous Black–Scholes equation | |
| Chen et al. | The white squire defense: Evidence from private investments in public equity | |
| Prajapat | A new subclass of close-to-convex functions | |
| Sander et al. | The resurgence of cultural borders during the financial crisis: The changing geography of Eurozone cross-border depositing | |
| EP3613000A4 (en) | SYSTEMS AND PROCEDURES FOR CONDUCTING TRANSACTIONS USING A REPLACEMENT PIN | |
| Wang et al. | Global estimates for non-uniformly nonlinear elliptic equations in a convex domain | |
| EP3818486C0 (en) | RECOVERING AN ORIGINAL CARD SECURITY CODE USED IN A CARD-BASED TRANSACTION | |
| Hanson et al. | Report writing for Static-99R and Static-2002R | |
| Burlakov et al. | E-COMMERCE TOOLS AS A FACTOR IN REDUCING TRANSACTION COSTS AGROFORMATIONS | |
| HK40089736A (en) | Neurologic toxicity assessment methods and systems for documenting changes in handwriting | |
| Tandiontong et al. | The Effect of The Public Accountant Firm Size, Issuer Size, Company Ownership, and Corporate Governance Implementation on Financial Statements Integrity | |
| Wang | Answer to the questions of Yanyan Li and Luc Nguyen in arXiv: 1302.1603 |